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Abstract Mammalian Vav signal transducer protein couples
tyrosine kinase signals with the activation of the Rho/Rac
GTPases, thus leading to cell differentiation and/or proliferation.
We have isolated and characterized the DroVav gene, the
homologue of hVav in Drosophila melanogaster. DroVav encodes
a protein (793 residues) whose similarity with hVav is 47% and
with hVav2 and hVav3 is 45%. DroVav preserves the unique,
complex structure of hVav proteins, including the ‘calponin
homology’, dbl homology, pleckstrin homology; SH2 and SH3
domains in addition to regions that are acidic rich, proline rich
and cysteine rich. DroVav is located on the X chromosome in
polytene interval 18A5;18B and is expressed in all stages of
development and in all tissues. In mammalian cells, DroVav is
tyrosine-phosphorylated in response to epidermal growth factor
receptor (EGFR) induction; in vitro, the DroVav SH2 region is
associated with tyrosine-phosphorylated EGFR. Thus, DroVav
probably plays a pivotal role as a signal transducer protein
during fruit fly development.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The identi¢cation of multiple proteins that participate in
tyrosine signal transduction cascades has been greatly facili-
tated by the discovery of a series of oncogenes that represent
aberrant forms of growth factor receptors, growth factors,
transducers of growth factor responses and transcription fac-
tors [1,2]. The vav proto-oncogene (Vav) is a cytoplasmic sig-
nal transducer that plays a pivotal role in hematopoietic cells
where it is exclusively expressed [3^6]. Vav is tyrosine-
phosphorylated in response to activation by one of several
cytokines, growth factors or antigen receptors [3,4,7,8]. Tyro-
sine phosphorylation of Vav regulates its activity as a gua-
nine-nucleotide exchange factor for the Rho-like small
GTPases RhoA, Rac1 and Cdc42, which lead to cytoskeletal
reorganization and activation of stress-activated protein ki-
nases (SAPK/JNKs) [9,10].
The role of Vav in vivo has been studied in a number of
ways. Embryonic stem cells homozygous for a null mutation
in Vav were injected into blastocysts of RAG-1 or RAG-2
de¢cient mice [11^13]. These manipulations led to a reduction
in the various populations of B and T cells normally observed
in wild type mice and to defective antigen receptor-mediated
proliferation of B and T cells [11^13]. However, T lympho-
cytes from Vav knockout mice respond abnormally to T cell
stimulation [5,6]. Both capping of the T cell receptor (TCR)
following cell activation and receptor recruitment of the actin
cytoskeleton to the CD3 j chain of the TCR are defective in
mice de¢cient for Vav. So also are interleukin-2 production,
cellular proliferation and cell cycle progression, activity of
NF-ATc, phosphorylation of SLP-76 and Ca2 mobilization
[5,6]. Hence in T cells, Vav integrates signals from lymphocyte
antigen receptors and costimulatory receptors to control dif-
ferentiation, proliferation and response to activation.
Vav is one part of a large family of proteins including
hVav2 with which it shares 64% similarity [14,15], and
hVav3 with which it shares 71% similarity [16]. The hVav2
and hVav3 proteins contain the characteristic structural mo-
tifs known to play a role in tyrosine-mediated signal trans-
duction, found in Vav. These motifs include the following
domains: a dbl homology domain (DH) that activates GTP-
bound proteins of the Rho-like family of proteins [17^19]; a
pleckstrin homology (PH) domain [20] ; a Src homology 2
(SH2) and two Src homology 3 (SH3) domains [21,22]; a
proline rich (PR) motif that allows it to bind to SH3 contain-
ing proteins [3] ; an acidic rich (AR) region [3]; a ‘calponin
homology’ (CH) region, which functions as an actin-binding
domain in other proteins [23] and a cysteine rich (CR) region.
Moreover, both hVav2 and hVav3 exhibit biochemical and
functional properties similar to those mediated by Vav. How-
ever, unlike Vav, Vav2 and Vav3 are also expressed in many
tissues/cells of non-hematopoietic origin [14^16]. Thus, the
Vav family of proteins is a novel family of signal transducers
that couple tyrosine kinase signals with the activation of the
Rho/Rac family of GTPases, events that are important in the
regulation of cell di¡erentiation and proliferation in most tis-
sues.
There are several cell surface receptor tyrosine kinase
(RTK) signaling pathways to the nucleus that have been
found to be conserved between mammalians and £ies. These
conserved pathways have been shown to control di¡erentia-
tion and morphogenesis in various developmental stages of
Drosophila melanogaster (reviewed in [24,25]). This similarity
makes it possible to use £ies to analyze the molecular mech-
anisms involved in signal transduction processes in a way that
would not be possible in mammalian cells. Here, we report on
the isolation and characterization of the D. melanogaster Vav
(DroVav), and provide initial evidence for its potential role in
signaling processes.
2. Materials and methods
2.1. Isolation of DroVav cDNA
An expressed sequence tag (EST) cDNA clone (GenBank accession
number AA736164) encoding a polypeptide with 50% homology to
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the carboxy-terminus of hVav was obtained from Research Genetics,
and the 1.8 kb cDNA fragment was used to screen a Vgt11 Drosophila
embryonal (8^12 h) cDNA library (kindly provided to us by Dr. T.
Volk). Eight positive clones were obtained, of which one was found
by PCR analysis to contain the presumptive 5P end. This DroVav
clone was digested with EcoRI, subcloned in pBluescript KS3 and
sequenced by an automated sequencer using overlapping oligonucleo-
tides that annealed to both strands (pID11; GenBank accession num-
ber AF218780). The alignment of the Vav proteins and structural
analysis of conserved motifs was performed by using the European
Bioinformatics Institute Clustalw program and the EMBL Simple
Modular Architecture Research Tool.
2.2. In situ hybridization to polytene chromosomes
Crawling third instar larvae were ¢xed, hybridized and stained as
previously described [26]. A genomic clone containing the DroVav
locus was labeled with biotin using the Bioprime DNA Labeling Sys-
tem (Gibco BRL).
2.3. RNA in situ hybridization
Both sense and antisense RNA DroVav probes from a cDNA clone
including base pairs 1083^1953 bp downstream from the initiation
codon were synthesized using T3 and T7 polymerases with a Maxi-
script in vitro transcription kit (Ambion). Overnight collections of
eggs from wild type and Df(1)JA27/FMZ,Scr-lacZ £ies were hybrid-
ized and detected as described previously [27]. Antisense lacZ probes
were also used to distinguish Df(1)JA27/Y embryos from those carry-
ing the FM7,Scr-lacZ balancer chromosome.
2.4. Reverse transcription (RT-) PCR, Southern and Northern blot
analyses
Poly-A RNA was extracted from wild type D. melanogaster at
various developmental stages with the Poly-A tract 1000 system
(Promega). cDNAs were prepared with an oligo-dT primer by using
the Superscript II reverse transcriptase (Gibco BRL). The resulting
cDNA mixtures were subjected to PCR ampli¢cation with the follow-
ing DroVav oligonucleotide primers: 5P-GAGACATCGCCGCTG-
CAC-3P and 5P-TCGCGGCCAATAGTGCGT-3P. The PCR products
were separated on 1.5% agarose gel, stained with ethidium bromide
and transferred to a nylon membrane (0.45 Wm) on which they were
hybridized with a DIG-labeled DroVav probe. The DroVav probe
employed was a cDNA clone extending from base pair 1083 down-
stream from the initiation codon to the 3P poly-A tail. To perform a
Northern blot analysis, the poly-A RNAs extracted as described
above were resolved on 1% morpholine propanesulfonic acid
(MOPS)/formaldehyde agarose gel, transferred onto a nylon mem-
brane (Nytrane 0.45 Wm) on which they were hybridized to the 32P-
labeled DroVav cDNA probe described above.
2.5. Bacterial fusion proteins
A DroVavSH2 glutathione-S-transferase (GST) fusion protein was
generated by a PCR-based methodology, using the full length DroVav
plasmid DNA (pID11) as a template. The 5P oligonucleotide con-
tained a BamHI restriction enzyme site (underlined): 5P-GGC-
GGGGGATCCAATTGGTTTGCGGGCAAC-3P and the 3P oligonu-
cleotide contained an EcoRI restriction enzyme site (underlined):
5P-CCGGGGGAATTCCACCTCCTTGTAGGGCCA-3P. The PCR
product was digested with BamHI and EcoRI restriction enzymes
and subcloned into the pGEX-2TK vector.
2.6. Mammalian expression vectors
hVav was cloned at the EcoRI site of the mammalian expression
vector driven by the CMV promoter, pCDNA3, thus generating
pCS114. Full length DroVav was generated by PCR ampli¢cation
by using the following primers: 5P-CCGGGGTCTAGAATGGC-
CAGCAGCAGT-3P and 5P-CCGGGGCTCGAGAAGCTCTTCG-
CTGGC-3P. The PCR product was digested with XbaI/XhoI (under-
lined above) and subcloned at the NheI/XhoI sites of pSecTagA
(Invitrogen), a mammalian expression vector driven by the CMV
promoter that contains a Myc epitope tag (pID18).
2.7. Binding of cell lysate proteins to bacterial GST fusion proteins
immobilized on glutathione Sepharose beads
Cell lysates were incubated with the appropriate fusion proteins
immobilized on glutathione Sepharose beads (5 Wg), resolved on so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and immunoblotted with antibodies (Abs) as described pre-
viously [7,28].
2.8. Cell culture
NIH3T3 murine ¢broblasts that overexpress the epidermal growth
factor receptor (EGFR) (HER14; [29]) and HEK293 were grown in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 10% calf
serum.
2.9. Gene transfer assays
HEK293 cells were transiently transfected with 10 Wg DNA of
various plasmid DNAs (see Section 3) by using FUGENE 6 (Boehr-
inger Mannheim). The e⁄ciency of transfection was con¢rmed by the
£uorescence of the green £uorescence plasmid included in the trans-
fection.
2.10. EGF stimulation
HEK293 cells transfected with various mammalian expression vec-
tors and HER14 cells grown to subcon£uence were starved in DMEM
containing 5 Wg/ml insulin and 5 Wg/ml transferrin for 24 h. Cells were
then treated with DMEM containing 0.5 Wg/ml human EGF at 37‡C
for 2 min, washed twice with phosphate-bu¡ered saline and lysed as
described above.
2.11. Abs
Monoclonal anti-phosphotyrosine (Ptyr) Abs, 4G10, anti-Myc Abs
used to detect the Myc-tagged DroVav and anti-Vav Abs were pur-
chased from UBI.
3. Results and discussion
We initially screened the Berkeley D. melanogaster Genome
Project (BDGP) ESTs databank for cDNA clones similar to
hVav. Our search led to the identi¢cation of an EST clone
(HL08101) that contains a 1.8 kb insert whose sequence cor-
responds to the carboxy-terminus of hVav. To isolate the
entire coding region of the D. melanogaster homologue of
human Vav (DroVav), we screened a D. melanogaster cDNA
library with the 1.8 kb insert of HL08101 as a probe. The
longest cDNA clone isolated, pID11, contained an open read-
ing frame of 2379 nucleotides with an ATG that conforms
with the consensus translation/initiation codon, a 490 bp 5P
untranslated region (UTR) and a 1.2 kb 3P UTR. A further
search of GenBank with the predicted DroVav protein se-
quence identi¢ed hVav as the most closely related protein.
Examination of pID11 revealed that it encoded a protein of
793 amino acid residues, which shares 47% similarity with
hVav and 45% similarity with both hVav2 and hVav3 (Fig.
1). An alignment of the domain structure of DroVav with
hVav, hVav2 and hVav3 reveals that DroVav preserves the
complex structure found in hVav proteins. These include a
CH domain, an AR region, a DH domain, a PH domain,
PR sequence, CR region, a SH2 and a SH3 domain (Fig.
1). These results strongly suggest that we have indeed isolated
the Drosophila homologue of Vav (DroVav).
The Vav family of proteins has a unique and highly char-
acteristic structure that includes numerous de¢ned known
functional regions [3,4,14^16]. In particular no other protein
or protein family includes the DH, PH, SH3 and SH2 regions.
Among the signal proteins in D. melanogaster, the structure of
DroVav is unique. One other Drosophila protein, DrtGEF, is
known to include the DH, PH and SH3 regions [30] ; however,
it lacks the SH2 domain that is shared by DroVav and hVav.
Though there is a great deal of homology between the Dro-
Vav and hVav proteins, they are not identical : DroVav lacks
the hVav amino-SH3 domain (SH3N). Sequence alignment
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between the two SH3 regions in the hVav polypeptide reveals
that the SH3 structure at the hVavSH3N di¡ers from that at
its carboxy-terminal end, hVavSH3C. As we have previously
reported, the hVavSH3C domain is more active in binding
proline rich proteins than is the hVavSH3N domain [31]. Se-
quence alignment of the amino acid residues of the Vav ho-
mologue in Caenorhabditis elegans (C. elegans Vav) with that
of hVav and DroVav (Fig. 1B) revealed that the CH, DH, PH
and SH2 regions are conserved, but that both SH3 regions are
missing. It is therefore conceivable that it were speci¢cally the
SH3 regions that evolved in the development of the protein
from C. elegans Vav to human Vav. Thus, the analysis of the
domain structures of the Vav proteins from various species of
increasing evolutionary complexity should highly be indicative
of evolutionary modi¢cations. Moreover, the identi¢cation of
Vav in species of di¡erent evolutionary complexity might be
highly suggestive of its pivotal role in signaling cascades.
Several of the conserved tyrosines in the human Vav pro-
teins are also found in DroVav (Fig. 1), including the hVav
Tyr142 (DroVav Tyr145) and the hVav Tyr209 (DroVav Tyr231).
Note that the target for phosphorylation by Src or Syk family
protein tyrosine kinases, resulting in activation of its exchange
activity, hVav Tyr174 [10], is not found in DroVav (Fig. 1A).
It was recently demonstrated that Tyr174 is not required for
the TCR-induced phosphorylation of Vav in vivo, but rather
that a mutation in this residue leads to gain in the ability of
Fig. 1. Comparison of amino acid residues of DroVav with hVav, hVav2 and hVav3 (A) and schematic representation of the domain structure
of Vav from C. elegans, D. melanogaster and humans (B). (A) The amino acid sequence of DroVav (dVav) is aligned with the three known
members of the hVav family of proteins. Symbols below the alignment represent: ‘*’ for identical residues; ‘ :’ for conserved residues and ‘.’ for
semi-conserved residues. The individual structural domains are boxed. Each domain/motif is also marked by arrows that designate the start
and end to the region in addition to the contraction of each region: CH, a ‘calponin homology’; AR, an acidic rich region; DH, a dbl homol-
ogy domain; PH, a pleckstrin homology domain; CR, cysteine rich; PR, proline rich; SH2, Src homology 2; and SH3, Src homology 3.
Shaded boxes represent structural domains absent in one or more of the proteins aligned. (B) Schematic representation of the domain structure
of C. elegans Vav, DroVav (dVav) and hVav. The numbers correspond to the amino acid boundaries of each domain.
FEBS 23549 14-4-00
I. Dekel et al./FEBS Letters 472 (2000) 99^104 101
Vav to up-regulate NF-AT activation [32,33]. These results
suggest that tyrosine residues additional to Tyr174 may also
play a critical role in the function of Vav proteins. Most of
the tyrosines in hVav that can be phosphorylated remain at
present unmapped. The fact that several of the conserved
tyrosines in the hVav proteins are also found in DroVav
might facilitate mapping and analyzing them.
To determine whether DroVav locus is involved in any of
the known mutations in D. melanogaster, we used a genomic
clone containing DroVav to localize it to polytene chromo-
somes. In situ hybridization showed that the DroVav locus
is located toward the base of the X chromosome in interval
18A5;18B (Fig. 2A). To ¢nd potential mutations in the Dro-
Vav locus, we searched the D. melanogaster database (£yba-
se.bio.indiana.edu) and found two deletion mutants,
Df(1)N19 (17A1;18A2) and Df(1)JA27 (18A5;18D), from
which parts of the 18A interval were missing. We repeated
the in situ hybridization to polytene chromosomes heterozy-
gous for the deletion chromosomes and a wild type chromo-
some. DroVav failed to hybridize to Df(1)JA27 chromosomes
while it hybridized to wild type homologues (Fig. 2B) and to
Df(1)N19 chromosomes (not shown). We conclude that
Df(1)JA27 deletion mutation removes the DroVav locus.
Human Vav proteins are signal transducers that are either
highly restricted in their tissue distribution, like hVav that is
exclusively expressed in the hematopoietic system [3], or are
widely distributed like hVav2 and hVav3 [14^16]. To deter-
mine the in vivo pattern of expression of DroVav in D. mel-
anogaster, we performed RNA in situ hybridization on D.
melanogaster embryos (Fig. 3A). An overnight collection of
eggs from wild type and Df(1)JA27/FMZ,Scr-lacZ £ies was
hybridized with sense and antisense DroVav probes. DroVav
RNA was found abundantly in 0^2 h embryos, prior to the
start of zygotic transcription (Fig. 3A, a). High levels of ubiq-
uitous DroVav RNA could also be detected following the
initiation of zygotic transcription (Fig. 3A, b^d). The level
of DroVav was greatly reduced in embryos that were
Df(1)JA27 deletion mutants and hence lacked the DroVav
locus (Fig. 3A, e). These embryos were identi¢ed by their
failure to hybridize to an antisense lacZ probe expressed
from the FMZ,Scr-lacZ chromosome (data not shown). In
addition, DroVav RNA was not detected in approximately
1/4 of the embryos analyzed, the same frequency expected
for Df(1)JA27/Y embryos. There is also a large maternal
contribution to embryonic DroVav. Using the Df(1)JA27 de-
¢ciency embryos, we have shown that maternal RNA is
present. This RNA disappears by the gastrulation stage. To
test whether DroVav is expressed in additional developmental
stages, we performed a RT-PCR analysis (Fig. 3B, upper pan-
el) ; our results indicated that DroVav is present in embryos
Fig. 2. In situ hybridization to polytene chromosomes localizes Dro-
Vav to the X chromosome. Crawling third instar larvae were ¢xed,
hybridized and stained as previously described [26]. A genomic clone
containing the DroVav locus was labeled with biotin and hybridized
with DroVav (A; arrow) and Df(1)JA27 chromosome (B; arrow-
head).
Fig. 3. Developmental expression (A), distribution (B) and size (C)
of the DroVav transcript. (A) Antisense RNA DroVav probe was
hybridized in situ with embryos of the following stages: early cleav-
age stage prior to the start of zygotic transcription (a), during cellu-
lar blastoderm (b), germ band extension (c) and germ band retrac-
tion (d) stages. In addition, embryos lacking the DroVav locus,
Df(1)JA27, were also used (e). (B) RT-PCR (upper panel) and
Southern blot analysis (lower panel) was performed on poly-A
RNA extracted from wild type (wt) Drosophila embryos (0^24 h;
lane 1), third instar larvae (lane 2), adult males (lane 3) and adult
females (lane 4) by using DroVav primers. The PCR product, en-
compassing nucleotides 1083^1482 (399 bp indicated by an arrow)
from the initiation codon, was separated on 1.5% agarose gel and
stained with ethidium bromide (B, upper panel). The reaction was
also performed on a mixture without DNA (lane 5). The DroVav
RT-PCR products were then transferred to a nylon membrane
which was hybridized with a DIG-labeled DroVav cDNA probe (B,
lower panel). Lane M refers to size marker PX174 digested with
HaeIII. (C) Northern blot analysis was performed on poly-A RNA
extracted from adult females, resolved on 1% MOPS/formaldehyde
agarose gel, transferred onto a nylon membrane and hybridized to a
32P-labeled DroVav cDNA probe. Similar results were obtained with
RNA extracted from embryos (0^24 h), third instar larvae and adult
males (data not shown).
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(0^24 h; lane 1), in third instar larvae (lane 2), and in both
adult males (lane 3) and females (lane 4). Southern blot anal-
ysis veri¢ed that the ampli¢ed fragment corresponds to Dro-
Vav (Fig. 3B, lower panel). Northern blot analysis revealed
two species of DroVav transcripts of 3.1 and 4.9 kb that we
found in embryos (a 0^24 h collection), in third instar larvae,
and in both adult males and females (Fig. 3C and data not
shown). The 3.1 kb transcript was found to be the major one
expressed as compared to the expression level of the 4.9 kb
transcript (Fig. 3C and data not shown). The 4.9 kb minor
transcript may represent either an alternatively spliced form of
DroVav or another unidenti¢ed related Vav signal transducer
protein. We are currently investigating these possibilities.
Together, our results showed that there are high levels of
DroVav expression in all embryonic tissues and at all subse-
quent stages of D. melanogaster development. This suggests
that DroVav may function in various signaling pathways in
D. melanogaster as do the hVav proteins in humans. The
particular in vivo spatial and temporal patterns of DroVav
function are yet to be identi¢ed.
A characteristic hallmark of Vav signal transducer proteins
is that they become phosphorylated on tyrosine residues in
response to EGF stimulation [7,34,35]. Furthermore, Vav pro-
teins are known to bind to the stimulated EGFR through
their SH2 region [7,34,35]. Since the encoded domain struc-
ture of DroVav strongly suggests that it may function as a
signal transducer protein, we tested its response to EGF stim-
ulation (Fig. 4). HEK293 cells were transiently transfected
with either an empty mammalian expression vector (pSec;
Fig. 4A, lanes 1 and 2), DroVav (Fig. 4A, lanes 3 and 4) or
hVav (Fig. 4A, lanes 5 and 6). We observed tyrosine phos-
phorylation of DroVav (lane 4) and hVav (lane 6) only when
the HEK293 cells had been stimulated with EGF (+; Fig. 4A,
upper panel). No tyrosine phosphorylation of these proteins
could be observed when the cells were non-induced (3 ; Fig.
4A, upper panel, lanes 3 and 5). Yet, comparable levels of
DroVav (Fig. 4A, middle panel, lane 3 vs. 4) and hVav
(Fig. 4A, lower panel, lane 5 vs. 6) were present in both the
non-induced and induced cells. Thus, we conclude that Dro-
Vav (92 kDa) is tyrosine-phosphorylated following the induc-
tion of signaling processes by EGF. Next, we tested whether
DroVav could associate with the stimulated EGFR through
its SH2 region. Fig. 4B illustrates that following incubation
with lysates of EGF-induced (+) HER14 cells, a 170 kDa
tyrosine-phosphorylated protein associated with DroVavSH2
(Fig. 4B, lane 4) and with hVavSH2 (Fig. 4B, lane 6), both
expressed as GST bacterial fusion proteins. By immunoblot-
ting with EGFR Abs, this 170 kDa was con¢rmed to be the
EGF receptor (data not shown). The binding of EGFR to
hVavSH2 is stronger than to DroVavSH2, probably due to
species-speci¢c di¡erences. These results indicate that the SH2
region of DroVav can associate with tyrosine-phosphorylated
proteins like EGFR.
We have shown that when DroVav is expressed in mamma-
lian cells, its tyrosine residues become phosphorylated in re-
sponse to EGF stimulation (Fig. 4A). Furthermore, the SH2
region of DroVav can associate with the phosphorylated
EGFR (Fig. 4B). These two results are highly compatible
with our earlier observations regarding hVav [7,34], and
thus strongly suggest that DroVav probably functions as a
signal transducer protein. Nevertheless, though our results
have not yet established DroVav as a target protein in
EGFR signaling cascades, they do suggest that the function
of DroVav is similar to that of hVav. This conclusion is fur-
ther strengthened by the fact that D. melanogaster RTK cas-
cades, consisting of signaling molecules like the EGF receptor
DER [36], and the GRB2 homologue DRK [37], are highly
conserved with their mammalian counterparts, where they
have been shown to interact with human Vav proteins
[7,34,38]. Moreover, the D. melanogaster homologues to the
Rho-like small GTPases (RhoA, Rac1 and Cdc42) have been
identi¢ed [39^41] and found to be similar to the mammalian
Vav-regulated Rho proteins [9,10]. These small GTPases have
been shown to be activators of the D. melanogaster JNK path-
way, part of the control system of developmental pathways
like embryonic dorsal closure [42,43] and muscular and neuro-
nal development [39]. Based on all these observations, we
predict that a high degree of conservation will be found be-
tween DroVav and hVav pathways.
Because there are several members in the Vav family of
proteins in humans, it is di⁄cult to di¡erentiate between pos-
sibly redundant and/or more complex functions. The fact that
the Vav genes have probably evolved from one ancestral gene
Fig. 4. Tyrosine phosphorylation of DroVav (A) and association of
DroVavSH2 with tyrosine-phosphorylated EGFR (B). (A) HEK293
cells that were transfected with either pSecTagA (pSec; lanes 1 and
2), DroVav (pID18; lanes 3 and 4) or hVav (pCS114; lanes 5 and
6) were either stimulated with EGF (+; lanes 2, 4 and 6) or non-
stimulated (3 ; lanes 1, 3 and 5). Lysates of these cells were immu-
noprecipitated with either anti-Myc Abs (lanes 1^4) or anti-Vav Abs
(lanes 5 and 6). The immunoprecipitated proteins were resolved on
SDS^PAGE, immunoblotted with anti-Ptyr Abs (upper panel) and
then rehybridized with either anti-Myc Abs (middle panel) or anti-
Vav Abs (lower panel). (B) Bacterial fusion proteins that express
GST (lanes 1 and 2), the SH2 region of DroVav (DroVavSH2;
lanes 3 and 4) and the SH2 of hVav (hVavSH2; lanes 5 and 6)
were immobilized on glutathione Sepharose beads and incubated
with lysates of cells overexpressing human EGFR (HER14) that
were either non-induced (3 ; lanes 1, 3 and 5) or induced (+; lanes
2, 4 and 6) with 0.5 Wg/ml EGF for 2 min. The proteins were then
resolved on SDS^PAGE and immunoblotted with anti-Ptyr Abs.
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together with the highly conserved and unique structure of
DroVav suggests that it is an important regulatory molecule
in the life of the cell/organism. Our studies of Vav in a lower
organism like the fruit £y D. melanogaster provide a powerful
tool to examine its function and to determine its role in signal-
ing cascades.
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